



Supplementary Figure 1. Vesicle permeability to IPTG. (A) A shrink-swell²⁻⁴ assay was used to assess whether IPTG was capable of crossing vesicle membranes. POPC:cholesterol vesicles with entrapped calcein were prepared in 10 mM MgCl₂, 100 mM KCl, 50 mM HEPES, pH 7.6 as described in the methods and subsequently purified by gel filtration chromatography with sepharose-4b. An aliquot of the vesicle sample was diluted two-fold with 1.0 M IPTG (final concentration = 0.5 M) at 37 °C. The reaction was monitored by fluorescence with excitation and emission wavelengths of 495 nm and 515 nm, respectively. The rapid decrease in fluorescence was due to both dilution with the solute solution and calcein self-quenching. If IPTG were capable of crossing the membrane, a recovery of fluorescence would have been observed. (B) The permeability of POPC vesicles to ribose was observable with the shrink-swell assay. The recovery in fluorescence after two-fold dilution with 1.0 M ribose (final concentration = 0.5 M) was due to equilibration of ribose and water across the membrane.

Supplementary Table 1. DNA sequences used in this study

NAME	NOTE	SEQUENCE
AS014A	T7 promoter, K30S E31T α HL-sfGFP	<p>ATTTAATACGACTCACTATAGATGGATTCTGATATCAATATCAAAAACGGCACCACCGATATCGGCTC CAATACCACCGTTAAAACCGGTGATCTGGTGACCTATGATTCTACCAACGGTATGCATAAAAAAGTGT TTTACTCGTTTATTGACGATAAAAACCATAACAAAAAACTGCTGGTCATCCGCACCAAAGGCACCATTG CGGGTCAATACCGTGTGACTCCGAAGAAGGTGCGAACAAAAGCGGTCTGGCTTGCCGTCTGCCTT TAAAGTGACAGTGCAACTGCCGGATAATGAAGTGCGCAGATTTTCAAGTTATTATCCGCGTAATAGCA TCGATACCAAAGAATATATGAGTACCCTGACCTATGGTTTTAATGGCAATGTTACCGGTGATGATACG GGTAAAATTGGCGGTCTGATTGGCGCCAATGTGTCCATTGGTCATACGCTGAAATACGTGCAACCGG ATTTCAAACCATTTCTGAAAAGTCCGACCGATAAAAAAGTGGGTTGAAAAGTTATCTTCAACAACATG GTGAATCAGAACTGGGGTCCGTACGATCGCGATTCTGGAATCCGGTTTATGGCAATCAGCTGTTTAT GAAAACCCGCAACGGTAGTATGAAAGCGGCGGATAATTTTCTGGACCCGAACAAAGCCTCAAGCCTG CTGTCCAGCGGTTTTAGCCCGATTTTCCACGGTTATTACCATGGATCGAAAGCCAGCAAACAGCA GACCAACATTGATGTGATCTACGAACGTGTGCGTGATGATTATCAACTGCATTGGACCTCAACCAATT GGAAAGGCACCAATACCAAAGATAAATGGACGGATCGCAGTTCAGAACGCTACAAAATTGATTGGGA AAAAGAAGAAATGACCAACGGATCCGGCAGCGTTCTATGCGTAAAGGCGAAGAGCTGTTCACTGG TGTCGTCCCTATTCTGGTGGAACTGGATGGTGTGTAACGGTCATAAGTTTTCCGTGCGTGGCGAGG GTGAAGGTGACGCAACTAATGGTAACTGACGCTGAAGTTCATCTGTACTACTGGTAACTGCCGGTA CCTTGGCCGACTCTGGTAACGACGCTGACTTATGGTGTTCAAGTCTTGTCTGTTATCCGGACCATATG AAGCAGCATGACTTCTCAAGTCCGCCATGCCGGAAGGCTATGTGCAGGAACGCACGATTTCTTTAA GGATGACGGCACGTACAAAACGCGTGCGGAAGTGAATTTGAAGGCGATAACCTGGTAAACCGCATT GAGCTGAAAGGCATTGACTTTAAAGAAGACGGCAATATCCTGGGCCATAAGCTGGAATACAATTTTA ACAGCCACAATGTTTACATCACCGCCGATAAACAAAAAATGGCATTAAAGCGAATTTTAAATTCGC CACAACGTGGAGGATGGCAGCGTGACGCTGGCTGATCACTACCAGCAAACACTCCAATCGGTGATG GTCCTGTTCTGCTGCCAGACAATCACTATCTGAGCACGCAAAGCGTTCTGTCTAAAGATCCGAACGAG AAACGCGATCATATGGTTCTGCTGGAGTTCGTAACCGCAGCGGGCATCACGCATGGTATGGATGAAC TGTACAAATAACTCGAGCACCACCACCACCACCCTGAGATCCGGCTGTAACAAAGCCCGAAAGGA AGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCT TGAGGGGTTTTTTG</p>
DT101A	T7 promoter, α HL- His tag	<p>TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCTCTAGAAATAATTTGTTAACT TTAAGAAGGAGATATACATATGGATTCTGATATCAATATCAAAAACGGCACCACCGATATCGGCTCC AATACCACCGTTAAAACCGGTGATCTGGTGACCTATGATAAAGAAAACGGTATGCATAAAAAAGTGT TTTACTCGTTTATTGACGATAAAAACCATAACAAAAAACTGCTGGTCATCCGCACCAAAGGCACCATTG GGGTCAATACCGTGTGACTCCGAAGAAGGTGCGAACAAAAGCGGTCTGGCTTGCCGTCTGCCTTT AAAGTGACAGTGCAACTGCCGGATAATGAAGTGCGCAGATTTTCAAGTTATTATCCGCGTAATAGCAT CGATACCAAAGAATATATGAGTACCCTGACCTATGGTTTTAATGGCAATGTTACCGGTGATGATACGG GTAAAATTGGCGGTCTGATTGGCGCCAATGTGTCCATTGGTCATACGCTGAAATACGTGCAACCGGAT TTCAAACCATTTCTGAAAAGTCCGACCGATAAAAAAGTGGGTTGAAAAGTTATCTTCAACAACATGGT GAATCAGAACTGGGGTCCGTACGATCGCGATTCTGGAATCCGGTTTATGGCAATCAGCTGTTTATGA AAACCCGCAACGGTAGTATGAAAGCGGCGGATAATTTTCTGGACCCGAACAAAGCCTCAAGCCTGCT GTCCAGCGGTTTTAGCCCGATTTTCCACGGTTATTACCATGGATCGCAAAGCCAGCAAACAGCAGA CCAACATTGATGTGATCTACGAACGTGTGCGTGATGATTATCAACTGCATTGGACCTCAACCAATTGG AAAGGCACCAATACCAAAGATAAATGGACGGATCGCAGTTCAGAACGCTACAAAATTGATTGGGAAA AAGAAGAAATGACCAACCTCGAGCACCACCACCACCCTGAGATCCGGCTGCTAACAAAGCCCG AAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAAC GGGTCTTGAGGGGTTTTTTG</p>
JF001A	T7 promoter, <u>theophylline</u> <u>riboswitch</u> α HL	<p>AATTAATACGACTCACTATAGGGTGATACCAGCATCGTCTTGATGCCCTTGGCAGCACCTGCTAAGG <u>TAACAACAAGATG</u>GATTCTGATATCAATATCAAAAACGGCACCACCGATATCGGCTCCAATACCACCG TTAAAACCGGTGATCTGGTGACCTATGATAAAGAAAACGGTATGCATAAA AAAGTGTTTTACTCGTTT ATTGACGATAAAAACCATAACAAAAAACTGCTGGTCATCCGCACCAAAGGCACCATTGCCGGTCAATA CCGTGTGTACTCCGAAGAAGGTGCGAACAAAAGCGGTCTGGCTTGCCGTCTGCCTTTAAAGTGACG CTGCAACTGCCGGATAATGAAGTGCGCAGATTTTCAAGTTATTATCCGCGTAATAGCATCGATACCAA</p>

		<p>AGAATATATGAGTACCCTGACCTATGGTTTTAATGGCAATGTTACCGGTGATGATACGGGTAAAATTG GCGGTCTGATTGGCGCAATGTGTCCATTGGTCATACGCTGAAATACGTGCAACCGGATTTCAAACC ATTCTGAAAAGTCCGACCGATAAAAAAGTGGGTTGAAAAGTTATCTTCAACAACATGGTGAATCAGA ACTGGGGTCCGTACGATCGCGATTCTGGAATCCGGTTTATGGCAATCAGCTGTTTATGAAAACCCGC AACGGTAGTATGAAAGCGGCGGATAATTTCTGGACCCGAACAAAGCCTCAAGCCTGCTGTCCAGCG GTTTTAGCCCGATTTTGGCCAGGTTATTACCATGGATCGAAAGCCAGCAAACAGCAGACCAACATT GATGTGATCTACGAACGTGTGCGTGATGATTATCAACTGCATTGGACCTCAACCAATTGGAAAGGCAC CAATACCAAAGATAAATGGACGGATCGCAGTTCAGAACGCTACAAAATTGATTGGGAAAAAGAAGAA ATGACCAACTTAACTCGAGCACCACCACCACCACCCTGAGATCCGGCTGCTAACAAAGCCCGAAAAGG AAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCTCTAAACGGGTC TTGAGGGGTTTTTTG</p>
RL067A	T7 promoter, α HL	<p>TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATCCCCTCTAGAAATAATTTGTTTAACT TTAAGAAGGAGATATACATATGGATTCTGATATCAATATCAAAACCGGCACCACCGATATCGGCTCC AATACCACCGTTAAAACCGGTGATCTGGTGACCTATGATAAAGAAAACGGTATGCATAAAAAAGTGT TTACTCGTTTATTGACGATAAAAAACCATAACAAAAAAGTCTGGTTCATCCGACCAAAGGCACCATTGC GGGTCAATACCGTGTACTCCGAAGAAGGTGCGAACAAAAGCGGTCTGGCTTGGCCGTCTGCCTTT AAAGTGACGCTGCAACTGCCGGATAATGAAGTGGCGCAGATTTAGATTATTATCCGCGTAATAGCAT CGATACCAAAGAATATAGTACCCTGACCTATGGTTTTAATGGCAATGTTACCGGTGATGATACGG GTAAAATTGGCGGTCTGATTGGCGCAATGTGTCCATTGGTCATACGCTGAAATACGTGCAACCGGAT TTCAAACCACTTCTGAAAAGTCCGACCGATAAAAAAGTGGGTTGAAAAGTTATCTTCAACAACATGGT GAATCAGAACTGGGGTCCGTACGATCGCGATTCTGGAATCCGGTTTATGGCAATCAGCTGTTTATGA AAACCCGCAACGGTAGTATGAAAGCGGCGGATAATTTCTGGACCCGAACAAAGCCTCAAGCCTGCT GTCCAGCGTTTTAGCCCGATTTTGGCCAGGTTATTACCATGGATCGAAAGCCAGCAAACAGCAGA CCAACATTGATGTGATCTACGAACGTGTGCGTGATGATTATCAACTGCATTGGACCTCAACCAATTGG AAAGGCACCAATACCAAAGATAAATGGACGGATCGCAGTTCAGAACGCTACAAAATTGATTGGGAAA AAGAAGAAATGACCAACTTAACTCGAGCACCACCACCACCACCCTGAGATCCGGCTGCTAACAAAGC CCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCTCT AAACGGGTCTTGGGGTTTTTTG</p>
RL069A	T7 promoter, <u>theophylline</u> <u>riboswitch</u> , K30S E31T α HL	<p>AATTAATACGACTCACTATAGGGTGATACCAGCATCGTCTTGATGCCCTTGGCAGCACCTGCTAAGG <u>TAACAACAAGATG</u>GATTCTGATATCAATATCAAAACCGGCACCACCGATATCGGCTCCAATACCACC GTTAAAACCGGTGATCTGGTGACCTATGATTCTACCAACGGTATGCATAAAAAAGTGTTTTACTCGTTT ATTGACGATAAAAAACCATAACAAAAAAGTCTGGTTCATCCGACCAAAGGCACCATTGCGGGTCAATA CCGTGTGTACTCCGAAGAAGGTGCGAACAAAAGCGGTCTGGCTTGGCCGTCTGCCTTTAAAGTGACG CTGCAACTGCCGGATAATGAAGTGGCGCAGATTTAGATTATTATCCGCGTAATAGCATCGATACCAA AGAATATATGAGTACCCTGACCTATGGTTTTAATGGCAATGTTACCGGTGATGATACGGGTAAAATTG GCGGTCTGATTGGCGCAATGTGTCCATTGGTCATACGCTGAAATACGTGCAACCGGATTTCAAACC ATTCTGAAAAGTCCGACCGATAAAAAAGTGGGTTGAAAAGTTATCTTCAACAACATGGTGAATCAGA ACTGGGGTCCGTACGATCGCGATTCTGGAATCCGGTTTATGGCAATCAGCTGTTTATGAAAACCCGC AACGGTAGTATGAAAGCGGCGGATAATTTCTGGACCCGAACAAAGCCTCAAGCCTGCTGTCCAGCG GTTTTAGCCCGATTTTGGCCAGGTTATTACCATGGATCGAAAGCCAGCAAACAGCAGACCAACATT GATGTGATCTACGAACGTGTGCGTGATGATTATCAACTGCATTGGACCTCAACCAATTGGAAAGGCAC CAATACCAAAGATAAATGGACGGATCGCAGTTCAGAACGCTACAAAATTGATTGGGAAAAAGAAGAA ATGACCAACGGATCCGCGAGCGGTTCTATGCGTAAAGGCGAAGAGCTGTTCACTGGTGTCTGCCCTA TTCTGGTGAAGTGGATGGTGTGATGTCAACGGTCATAAGTTTTCCGTGCGTGGCGAGGGTGAAGGTGA CGCAACTAATGGTAAACTGACGCTGAAGTTCATCTGTACTACTGGTAAACTGCCGTACCTTGGCCGA CTCTGGTAAACGACGCTGACTTATGGTGTTCAGTGCTTTGCTGTTATCCGGACCATATGAAGCAGCAT GACTTCTTCAAGTCCGCCATGCCGGAAGGCTATGTGCAGGAACGCACGATTTCTTTAAGGATGACGG CACGTACAAAACGCGTGCGGAAGTGAATTTGAAGGCGATACCTGGTAAACCGCATTGAGCTGAAA GGCATTGACTTTAAAGAAGACGGCAATATCCTGGGCCATAAGCTGGAATACAATTTAAGCCACAA TGTTTACATCACCGCCGATAAACAAAAAATGGCATTAAAGCGAATTTTAAATTCGCCACAACGTGG AGGATGGCAGCGTGCAGCTGGCTGATCACTACCAGCAAACACTCCAATCGGTGATGGTCTGTTCTG CTGCCAGACAATCACTATCTGAGCACGCAAAGCGTTCTGTCTAAAGATCCGAACGAGAAACGCGATCA TATGGTCTGCTGGAGTTCGTAACCGCAGCGGGCATCACGCATGGTATGGATGAACTGTACAATAA</p>

		CTCGAGCACCACCACCACCACCCTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGG CTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAACCGGTCTTGAGGGTTTT TTG
SP002A	T7 promoter, αHL-sfGFP	ATTTAATACGACTCACTATAG ATG GATTCTGATATCAATATCAAACCGGCACCACCGATATCGGCTC CAATACCACCGTTAAAACCGGTGATCTGGTGACCTATGATAAAGAAAACGGTATGCATAAAAAAGTGT TTTACTCGTTTTATTGACGATAAAAAACCATAACAAAAAACTGCTGGTCATCCGCACCAAAGGCACCATTG CGGGTCAATACCGTGTGACTCCGAAGAAGGTGCGAACAAAAGCGGTCTGGCTTGGCCGTCTGCCTT TAAAGTGACGCTGCAACTGCCGATAATGAAGTGGCGCAGATTTTCAATTATTATCCGCGTAATAGCA TCGATACCAAAGAATATATGAGTACCCTGACCTATGGTTTTAATGGCAATGTTACCGGTGATGATACG GGTAAAATTGGCGGTCTGATTGGCGCAATGTGTCCATTGGTCATACGCTGAAATACGTGCAACCGG ATTTCAAACCACTTCTGGAAAGTCCGACCGATAAAAAAGTGGGTTGGAAAGTTATCTTCAACAACATG GTGAATCAGAAGTGGGGTCCGTACGATCGCGATTCTGGAATCCGGTTTATGGCAATCAGCTGTTTAT GAAAACCGCAACGGTAGTATGAAAGCGGCGGATAATTTTCTGGACCCGAACAAAGCCTCAAGCCTG CTGTCCAGCGGTTTTAGCCCGGATTTTGCCACGGTATTACCATGGATCGAAAGCCAGCAAACAGCA GACCAACATTGATGTGATCTACGAACGTGTGCGTGATGATTATCAACTGCATTGGACCTCAACCAATT GGAAAGGCACCAATACCAAAGATAAATGGACGGATCGCAGTTCAGAACGCTACAAAATTGATTGGGA AAAAGAAGAAATGACCAACGGATCCGGCAGCGGTTCT ATG CGTAAAGGCGAAGAGCTGTTCACTGG TGTCGTCCCTATTCTGGTGGAACTGGATGGTGTGCAACGGTCATAAGTTTTCCGTGCGTGCCGAGG GTGAAGGTGACGCAACTAATGGTAACTGACGCTGAAGTTTCTGTACTACTGGTAACTGCCGGTA CCTTGGCCGACTCTGGTAACGACGCTGACTTATGGTGTTCAAGTCTTGTCTGTTATCCGGACCATATG AAGCAGCATGACTTCTCAAGTCCGCCATGCCGGAAGGCTATGTGCAGGAACGCACGATTTCTTTAA GGATGACGGCACGTACAAAACGCGTGCAGGAAAGTAAATTTGAAGGCGATACCTGGTAAACCGCATT GAGCTGAAAGGCATTGACTTTAAAGAAGACGCAATATCCTGGGCCATAAGCTGGAATACAATTTTA ACAGCCACAATGTTTACATCACCGCCGATAAACAAAAAAATGGCATTAAAGCGAATTTTAAATTCGC CACAACGTGGAGGATGGCAGCGTGCAGCTGGCTGATCACTACCAGCAAAACACTCCAATCGGTGATG GTCCTGTTCTGCTGCCAGACAATCACTATCTGAGCACGCAAAGCGTTCTGTCTAAAGATCCGAACGAG AAACGCGATCATATGGTCTGCTGGAGTTCTGTAACCGCAGCGGCATCACGATGGTATGGATGAAC TGTAACA TA ACTCGAGCACCACCACCACCACCCTGAGATCCGGCTGCTAACAAAGCCCGAAAGGA AGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAACCGGTCT TGAGGGGTTTTTTG
SP011A	T7 promoter, <u>theophylline</u> <u>riboswitch</u> , αHL-sfGFP	AATTAATACGACTCACTATAGGGTGATACCAGCATCGTCTTGATGCCCTTGGCAGCACCTGCTAAGG <u>TAACAACAAG</u> ATG GATTCTGATATCAATATCAAACCGGCACCACCGATATCGGCTCCAATACCACC GTAAAACCGGTGATCTGGTGACCTATGATAAAGAAAACGGTATGCATAAAAAAGTGTTTTACTCGTT TATTGACGATAAAAAACCATAACAAAAAACTGCTGGTCATCCGCACCAAAGGCACCATTGCGGGTCAAT ACCGTGTGACTCCGAAGAAGGTGCGAACAAAAGCGGTCTGGCTTGGCCGTCTGCCTTTAAAGTGCA GCTGCAACTGCCGATAATGAAGTGGCGCAGATTTTCAATTATTATCCGCGTAATAGCATCGATACCA AAGAATATATGAGTACCCTGACCTATGGTTTTAATGGCAATGTTACCGGTGATGATACGGGTAATAAT GGCGGTCTGATTGGCGCAATGTGTCCATTGGTCATACGCTGAAATACGTGCAACCGGATTTCAAAC CATTCTGGAAAGTCCGACCGATAAAAAAGTGGGTTGGAAAGTTATCTTCAACAACATGGTGAATCAG AACTGGGGTCCGTACGATCGCGATTCTGGAATCCGGTTTATGGCAATCAGCTGTTTATGAAAACCG CAACGGTAGTATGAAAGCGGCGGATAATTTTCTGGACCCGAACAAAGCCTCAAGCCTGCTGTCCAGC GGTTTTAGCCCGGATTTTGCCACGGTATTACCATGGATCGCAAAGCCAGCAAACAGCAGACCAACAT TGATGTGATCTACGAACGTGTGCGTGATGATTATCAACTGCATTGGACCTCAACCAATTGGAAGGCA CCAATACCAAAGATAAATGGACGGATCGCAGTTCAGAACGCTACAAAATTGATTGGGAAAAAGAAGA AATGACCAACGGATCCGGCAGCGGTTCT ATG CGTAAAGGCGAAGAGCTGTTCACTGGTGTGTCCTT ATTCTGGTGGAACTGGATGGTGTGCAACGGTCATAAGTTTTCCGTGCGTGCCGAGGGTGAAGGTG ACGCAACTAATGGTAACTGACGCTGAAGTTTCTGTACTACTGGTAACTGCCGGTACCTTGGCCG ACTCTGGTAACGACGCTGACTTATGGTGTTCAAGTCTTGTCTGTTATCCGGACCATATGAAGCAGCAT GACTTCTTCAAGTCCGCCATGCCGGAAGGCTATGTGCAGGAACGCACGATTTCTTTAAGGATGACGG CACGTACAAAACGCGTGCAGGAAAGTAAATTTGAAGGCGATACCTGGTAAACCGCATTGAGCTGAAA GGCATTGACTTTAAAGAAGACGCAATATCCTGGGCCATAAGCTGGAATACAATTTTAAACGCCACAA TGTTTACATCACCGCCGATAAACAAAAAAATGGCATTAAAGCGAATTTTAAATTCGCCACAACGTGG AGGATGGCAGCGTGCAGCTGGCTGATCACTACCAGCAAAACACTCCAATCGGTGATGGTCTGTTCTG

		CTGCCAGACAATCACTATCTGAGCACGCAAAGCGTTCTGTCTAAAGATCCGAACGAGAAACGCGATCA TATGGTTCTGCTGGAGTTCGTAACCGCAGCGGGCATCACGCATGGTATGGATGAACTGTACAAA TAA CTCGAGCACCACCACCACCACCCTGAGATCCGGCTGCTAACAAAGCCGAAAGGAAGCTGAGTTGG CTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAACGGGTCTTGAGGGTTTTT TTG
--	--	--

Start and stop codons are in bold and the theophylline riboswitch is underlined. The T7 promoter and T7 terminator sequences are TAATACGACTCACTATA and CTAGCATAACCCCTTGGGGCCTCTAACGGGTCTTGAGGGTTTTTTG, respectively.

Supplementary Table 2. The activity of cell-free expressed α HL

construct name	$t_{1/2}$ (min)	Comments
JF001A	> 30	α HL behind theophylline riboswitch in the absence of theophylline
JF001A	16.5	α HL behind theophylline riboswitch in the presence of theophylline
DT101A	> 30	α HL-His tagged
SP002A	4.5	α HL-GFP
RL067A	10.0	α HL
Sigma-Aldrich α HL	9.5	commercial α HL
CD101A ¹	> 30	GFP
AS014A	> 30	K30S E31T α HL-GFP lacking an internal RBS

Each construct was expressed *in vitro* with the PURE system and subsequently added to rabbit red blood cells. Hemolysis was measured by attenuation as described in the methods. When indicated, the theophylline concentration was 1.5 mM. Sigma-Aldrich α HL indicates purchased purified protein and was not *in vitro* expressed.

Supplementary References

1. Lentini R., *et al.* Fluorescent proteins and in vitro genetic organization for cell-free synthetic biology. *ACS Synth. Biol.* **2**, 482-489 (2013).
2. Bittman R. & Blau L. Permeability behavior of liposomes prepared from fatty acids and fatty acid methyl esters. *Biochim. Biophys. Acta* **863**, 115-120 (1986).
3. Chen P. Y., Pearce D. & Verkman A. S. Membrane water and solute permeability determined quantitatively by self-quenching of an entrapped fluorophore. *Biochemistry* **27**, 5713-5718 (1988).
4. Sacerdote M. G. & Szostak J.W. Semipermeable lipid bilayers exhibit diastereoselectivity favoring ribose. *Proc. Natl Acad. Sci. USA.* **102**, 6004-6008 (2005).